Albumin Indications in Cirrhosis
Albumin is strongly indicated in cirrhosis for large-volume paracentesis (≥5 L), spontaneous bacterial peritonitis, and hepatorenal syndrome type 1, with specific weight-based or volume-based dosing protocols that differ by indication.
Established Indications with Strong Evidence
Large-Volume Paracentesis (≥5 L)
- Administer 8 g of albumin per liter of ascites removed when the total volume exceeds 5 L (e.g., 40 g for a 5 L tap, 80 g for a 10 L tap). 1, 2
- Use 20% or 25% hyperoncotic albumin solutions only; 5% albumin is inadequate for preventing post-paracentesis circulatory dysfunction (PICD). 2, 3
- Infuse albumin after paracentesis completion, not during the procedure, over 1–2 hours to avoid cardiac overload in patients with cirrhotic cardiomyopathy. 2, 4
- Without albumin, PICD occurs in 70–80% of patients versus ≈18% with proper replacement; renal impairment develops in ≈21% versus 0% when albumin is given. 2, 4
- For paracentesis <5 L, albumin is optional but should be considered in patients with acute-on-chronic liver failure or high risk of post-paracentesis acute kidney injury. 2, 3
Common pitfall: Underdosing albumin (e.g., 4 g/L instead of 8 g/L) markedly increases PICD incidence and renal complications. All major hepatology societies endorse the 8 g/L standard. 1, 2
Spontaneous Bacterial Peritonitis (SBP)
- Give 1.5 g/kg albumin within 6 hours of SBP diagnosis, followed by 1.0 g/kg on day 3. 1
- This regimen reduces renal impairment from ≈33% to ≈10% and mortality from ≈41% to ≈22% compared with antibiotics alone. 1, 3
- Patients with bilirubin >4 mg/dL or creatinine >1 mg/dL derive the greatest benefit from this protocol. 1, 3
Critical distinction: SBP requires weight-based dosing, whereas large-volume paracentesis uses volume-based dosing calculated solely on ascites removed. 2, 3
Hepatorenal Syndrome Type 1 (HRS-AKI)
- Albumin should be combined with a vasoconstrictor (preferably terlipressin, or alternatively norepinephrine or octreotide + midodrine). 1, 3
- Standard dosing: 1 g/kg on day 1 (maximum 100 g), then 20–40 g daily concurrent with vasoconstrictor therapy. 2, 3
- The 2024 International Collaboration for Transfusion Medicine Guidelines note that most prior trials used albumin in both arms (albumin vs albumin + terlipressin), making it difficult to isolate albumin's independent effect. 1
Indications with Insufficient or Conflicting Evidence
Long-Term Albumin for Uncomplicated Ascites
- The ATTIRE trial (777 patients) showed no benefit from daily albumin infusions targeting serum albumin ≥3 g/dL and demonstrated significantly higher rates of pulmonary edema and fluid overload in the albumin group. 1, 2
- Routine daily albumin to achieve target serum levels is not recommended and may cause harm. 1, 2
- One earlier unblinded trial suggested benefit, but methodological limitations (weekly health care interactions in albumin group only) confound interpretation. 1
Severe Hypoalbuminemia with Refractory Edema
- No high-quality evidence supports albumin for correction of hypoalbuminemia per se or for nutritional purposes. 3, 5
- The 2024 guidelines explicitly state albumin should not be used for uncomplicated ascites or routine hypoalbuminemia correction. 1, 3
Non-SBP Infections in Cirrhosis
- Albumin should not be used for extraperitoneal infections; the ATTIRE trial subgroup with infections showed no improvement in the composite endpoint of new infections, kidney dysfunction, or death. 1, 3
Dosing Algorithm by Clinical Scenario
| Clinical Scenario | Albumin Dose | Timing | Evidence Strength |
|---|---|---|---|
| Paracentesis ≥5 L | 8 g per liter removed | After procedure, over 1–2 h | Strong [1,2] |
| Paracentesis <5 L (high-risk) | 8 g per liter (optional) | After procedure | Conditional [2,3] |
| SBP | 1.5 g/kg → 1.0 g/kg (day 3) | Within 6 h, then day 3 | Strong [1] |
| HRS type 1 | 1 g/kg day 1 (max 100 g), then 20–40 g daily | With vasoconstrictor | Guideline-endorsed [1,2,3] |
| Uncomplicated ascites | Not indicated | — | Strong against [1,2] |
Post-Procedure Management
Diuretic Therapy After Paracentesis
- Restart diuretics within 1–2 days after large-volume paracentesis to prevent rapid ascites re-accumulation (93% recurrence without diuretics vs 18% with spironolactone). 2, 4
- Recommended regimen: spironolactone 100 mg daily (titrated up to 400 mg) plus furosemide 40 mg daily (up to 160 mg), maintaining a 100:40 mg ratio. 1, 2, 4
- Diuretic re-introduction does not increase PICD risk when adequate albumin has been provided. 2
Monitoring Protocol (Days 1–6)
- Daily serum sodium: hyponatremia occurs in ≈17% without albumin versus ≈8% with proper replacement. 2, 4
- Daily serum creatinine: rising creatinine >0.3 mg/dL from baseline suggests evolving hepatorenal syndrome. 2
- Mean arterial pressure: declines >8 mmHg may signal advancing circulatory failure. 2
Critical Safety Considerations
Avoid Synthetic Colloids
- Dextran-70, polygeline, hydroxyethyl starch, and gelatin are inferior to albumin and cause greater renin-angiotensin-aldosterone system activation, higher hyponatremia rates, and worse clinical outcomes. 1, 2, 4
- The 2010 EASL guidelines explicitly state that plasma expanders other than albumin are not recommended for large-volume paracentesis. 2
Infusion Rate and Cardiac Overload
- Rapid albumin infusion can precipitate cardiac overload in patients with cirrhotic cardiomyopathy; always infuse over 1–2 hours. 2, 4
Normal Saline Contraindication
- Normal saline is contraindicated in ascites management because it contains 154 mmol/L sodium and worsens salt retention and ascites. 4, 3
Red Flags Requiring Escalation
- Fever or abdominal pain after paracentesis mandates diagnostic tap to exclude SBP; if confirmed, escalate to SBP albumin protocol (1.5 g/kg within 6 h, then 1.0 g/kg day 3). 2
- Worsening hypotension or oliguria despite albumin correction warrants ICU-level monitoring and consideration of vasoconstrictor therapy. 2
- Rising creatinine suggests hepatorenal syndrome, associated with 21% six-month mortality in refractory ascites. 2